From October 17–21, the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) will take place in Vienna.
This year, we have exciting developments to share. We are eager to present the latest clinical advancements of Terbium-161, including the first evidence demonstrating the superiority of Tb-161. Furthermore, we will provide exclusive insights into our newly established production facility, which is fully dedicated to securing the future supply of Tb-161.
You are warmly invited to visit us at Booth #321, Hall X3. Our team will be on hand to show you our latest progress and discuss how we can best support your projects. We look forward to welcoming you in Vienna!